Evidence map›Paper›PMID 30050300›Full record

ReviewNeuropsychiatric disease and treatment2018

Cortical gyrification in schizophrenia: current perspectives.

Yukihisa Matsuda, Kazutaka Ohi

Abstract readReview
In one paragraph

Review in Neuropsychiatric disease and treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Cortical morphological heterogeneity of schizophrenia and its relationship with glutamatergic receptor variations.European psychiatry : the journal of the Association of European Psychiatrists · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yukihisa MatsudaFaculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Hiroshima, Japan.
Kazutaka OhiDepartment of Neuropsychiatry, Kanazawa Medical University, Ishikawa, Japan, ohi@kanazawa-med.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cerebral cortex of the human brain has a complex morphological structure consisting of folded or smooth cortical surfaces. These morphological features are referred to as cortical gyrification and are characterized by the gyrification index (GI). A number of cortical gyrification studies have been published using the manual tracing GI, automated GI, and local GI in patients with schizophrenia. In this review, we highlighted abnormal cortical gyrification in patients with schizophrenia, first-episode schizophrenia, siblings of patients, and high-risk and at-risk individuals. Previous researches also indicated that abnormalities in cortical gyrification may underlie the severity of clinical symptoms, neurological soft signs, and executive functions. A substantial body of research has been conducted; however, some researches showed an increased GI, which is called as "hypergyria," and others showed a decreased GI, which is called as "hypogyria." We discussed that different GI methods and a wide variety of characteristics, such as age, sex, stage, and severity of illness, might be important reasons for the conflicting findings. These issues still need to be considered, and future studies should address them.

Indexed as

cortical gyrificationgyrification indexschizophrenia

Identifiers

PMID30050300
PMCPMC6055839

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.